Dr.Einhorn and Dr. HannaDrs. Einhorn & Hanna

IU’s lung cancer research team is dedicated to finding ways to target and personalize treatment for each individual patient. IU research recently demonstrated that adding immunotherapy to traditional chemotherapy and radiation leads to dramatic improvements in survival for those with stage III disease. Philanthropic support helps IU researchers continue to make strides in the treatment of the world’s deadliest form of cancer.

Dr. Einhorn’s former fellow Nasser Hanna, M.D., now leads the program. He boils down the philosophy of lung cancer research at Indiana University Melvin and Bren Simon Comprehensive Cancer Center to a simple question.

“We look at the problem of lung cancer and determine what IU’s unique contributions can be,” Hanna said. “We ask, ‘What research will NOT be done if IU does not do it?’”

Hanna, who serves as the Tom and Julie Wood Foundation Professor of Lung Cancer Clinical Research, leads a team of 10 clinical lung cancer researchers. Their collective goal is to conduct research that will help inform clinical decisions, such as how much chemotherapy to give a patient or whether adding immunotherapy will improve outcomes.

Currently, IU’s team is organizing research efforts around three overarching themes: personalizing therapy for individual patients, maximizing the impact of immunotherapy in early-stage lung cancer, and overcoming resistance to platinum-based therapies. IU’s findings translate to better care for patients in Indiana and around the world.

To learn more on the lung cancer research being conducted, view our Lung Cancer Research Update.

Give Now Lung Cancer Research Fund: Gifts to the Lung Cancer Research Fund support the most pressing needs within lung cancer research within the Division of Hematology/Oncology in the Department of Medicine at the IU School of Medicine.